Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
48 studies found for:    PDGFRA
Show Display Options
Rank Status Study
1 Completed Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)
Condition: Gastrointestinal Stromal Tumors
Intervention: Other: Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years
2 Recruiting Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
Condition: Recurrent/Refractory Glioblastoma
Intervention: Drug: crenolanib
3 Recruiting Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST
Condition: Gastrointestinal Stromal Tumors With a D842V Mutation in the PDGFRA Gene.
Interventions: Drug: Crenolanib;   Drug: Placebo
4 Completed Study on the Evolution of Genes Mutation Related With Gastrointestinal Stromal Tumors
Conditions: Full Gene Sequences of c-KIT、PDGFRA and DOG1 Are Analyzed With the Screening-sequencing Approach;   Investigate the Characteristics and Variations Associated With the Different Gene Mutations of c-KIT、PDGFRA and DOG1 in GIST Patients
Intervention:
5 Completed Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: anti-PDGFR alpha monoclonal antibody IMC-3G3;   Biological: ramucirumab
6 Completed A Study of IMC-3G3 in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors
Condition: Gastrointestinal Stromal Tumor (GIST)
Intervention: Biological: IMC-3G3
7 Completed Phase II Study of Crenolanib (CP-868,596), for the Treatment of Patients With Advanced Gastrointestinal Stromal Tumors With the D842-related Mutations and Deletions in the PDGFRA Gene
Condition: D842-related Mutant GIST
Intervention: Drug: Crenolanib besylate (CP-868,596-26), Dose: 140mg BID
8 Recruiting Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
Condition: Advanced Cancer
Intervention: Drug: MGCD516
9 Completed A Study of IMC-3G3 in Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: IMC-3G3;   Drug: Mitoxantrone
10 Terminated A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Drug: imatinib mesylate
11 Active, not recruiting The Oncopanel Pilot (TOP) Study
Conditions: Colorectal Cancer Metastatic;   Advanced Non-Small Cell Lung Carcinoma;   Advanced Melanoma;   Gastrointestinal Stromal Tumors;   Patients With Diagnosed Malignancies Being Considered for Clinical Trials
Intervention:
12 Completed Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)
Condition: Sarcoma
Interventions: Drug: imatinib mesylate;   Drug: imatinib
13 Recruiting Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
Condition: Malignant Neoplasm
Interventions: Drug: ponatinib hydrochloride;   Other: laboratory biomarker analysis
14 Active, not recruiting A Study of IMC-3G3 in Soft Tissue Sarcoma
Condition: Sarcoma, Soft Tissue
Interventions: Biological: IMC-3G3;   Drug: doxorubicin;   Drug: dexrazoxane
15 Completed Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available
Condition: Solid Tumors
Intervention: Biological: IMC-3G3
16 Active, not recruiting A Study of Paclitaxel/Carboplatin With or Without IMC-3G3 in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Condition: Non-Small Cell Lung Cancer
Interventions: Biological: IMC-3G3;   Drug: Paclitaxel;   Drug: carboplatin
17 Completed A Study of Liposomal Doxorubicin With or Without IMC-3G3 in Platinum-refractory or Resistant Advanced Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Biological: IMC-3G3;   Drug: liposomal doxorubicin
18 Completed Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian Cancer
Condition: Platinum-resistant Advanced Ovarian Cancer
Intervention: Drug: Pazopanib
19 Completed A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.
Condition: Cancer
Intervention: Drug: MEDI-575
20 Recruiting A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Conditions: Gastrointestinal Stromal Tumors;   Aggressive Systemic Mastocytosis;   Advanced Cancers
Intervention: Drug: DCC-2618

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years